Investing in global healthcare

Even before the Coronavirus pandemic, we knew that healthcare budgets in many countries were stretched, and the pressure to develop new medicines, new health products and more efficient tools and practices was building – thanks to the demands of an ageing and increasingly health-conscious world population.

The past few weeks have magnified this problem and today, as governments around the world try to control the spread of the disease so that it doesn’t overwhelm our healthcare systems, all eyes are on the industry and its workers. We are clapping our NHS workers and following closely the developments of biotech companies and scientists, as they work 24/7 trying to find medicines, tests and, ultimately, a vaccine that can protect us from the virus.

What the industry is doing to tackle COVID-19

Earlier this week, James Douglas, co-manager of Polar Capital Global Healthcare Trust, told us how the healthcare sector is responding to the coronavirus crisis. From short-term needs such as tests, ventilators and vaccines, through to longer term investment in our global healthcare infrastructure and the way we access services, the implications are significant.

Even healthcare not immune from the global shutdown

According to Mark Kelly, a healthcare analyst at Brown Advisory, one area that has been hurt by the crisis is demand for non-elective surgeries.

“‘Elective’ is surgery that is scheduled in advance because it is not an emergency or life threatening,” he said. “What we’re seeing is ‘non-elective’ surgery turning out to be ‘elective’ (and pushed back) – unfortunately even cancer patients and those requiring brain surgery or spinal procedures are being prioritised below coronavirus patients.

“Therefore, we have concern for providers of hospital systems (for those procedures that are being pushed back). Their margins are low even in the good times. They will face severe financial difficulties given the reduction in demand. Today, we favour pharmaceuticals, managed care and companies that serve the biotechnology industry.

His colleague, Bertie Thomson, who is co-manager of Brown Advisory Global Leaders fund, added: “We like healthcare, and we really like some of the business models in medical tools and devices etc, such as Edwards Lifesciences (a Global Leaders investment since day one).

“Nonetheless we have been underweight healthcare for a couple of years – primarily due to valuation – the companies were simply too expensive for us, so we invested elsewhere.

“The only new investment we made in 2019 was in Roche Pharma, a global healthcare company headquartered in Switzerland. Roche has been one of our best performers in 2020, in part due to the defensiveness perceived in the healthcare sector.

“Edwards Lifesciences is a developer and manufacturer of technologies used to treat structural heart disease. It is clearly exposed to the delays we are seeing in elective surgery and we will no doubt see sales stall in the first half of 2020. But at the moment this is a short-term demand issue, and not a competitor stealing customers. Cashflows in 3-4 years do not appear to have materially changed at the moment, despite near-term disruption.”

Investing in our future healthcare services

The importance of the health care sector to both society and the global economy is undeniable. Global health care spending is likely to exceed $10 trillion per year by 2022, according to Deloitte’s 2019 Global Health Care Outlook. And, unsurprisingly, health care has also grown to become the second-largest sector in public equity markets.

Intractable challenges and obstacles remain – before the coronavirus, the sector had issues around rising costs, rapid changes to the models used to deliver care, impacts from climate change and pollution, and massive inequities in access to care.

But when the worst of the crisis has passed, we believe the quest to deliver the holy grail of better healthcare for less money, will continue. And the investment opportunities will be plentiful.

So, as we begin a new tax year and have new ISA and pension allowances to think about, maybe consider investing in global healthcare…

Three funds investing in healthcare

  1. Polar Capital Global Healthcare Trust: this specialist trust invests in a healthcare companies all over the world, and predominantly from four sub-sectors: pharmaceuticals, biotechnology, medical technology and healthcare services. The portfolio is split into two segments: growth and innovation with a circa 90/10 split.
  2. Baillie Gifford Global Discovery: this global smaller companies fund invests in innovative businesses that are capable of changing the world. It currently has 39.8%* of the portfolio invested in healthcare companies including Alnylam Pharmaceuticals, a biopharmaceutical company and Teladoc, a global virtual care provider.
  3. Comgest Growth Europe ex UK: this is a high conviction fund investing in high-quality European companies. The portfolio currently has just 36 holdings, a third of which are in healthcare related*. The largest is Roche, the Swiss pharmaceuticals and diagnostics company*.

*Source: Fund factsheet, 29 February 2020

This article is provided for information only. The views of the author and any people quoted are their own and do not constitute financial advice. The content is not intended to be a personal recommendation to buy or sell any fund or trust, or to adopt a particular investment strategy. However, the knowledge that professional analysts have analysed a fund or trust in depth before assigning them a rating can be a valuable additional filter for anyone looking to make their own decisions. Past performance is not a reliable guide to future returns. Market and exchange-rate movements may cause the value of investments to go down as well as up. Yields will fluctuate and so income from investments is variable and not guaranteed. You may not get back the amount originally invested. Tax treatment depends of your individual circumstances and may be subject to change in the future. If you are unsure about the suitability of any investment you should seek professional advice. Whilst FundCalibre provides product information, guidance and fund research we cannot know which of these products or funds, if any, are suitable for your particular circumstances and must leave that judgement to you. Before you make any investment decision, make sure you’re comfortable and fully understand the risks. Further information can be found on Elite Rated funds by simply clicking on the name highlighted in the article.